Vamifeport
- Generic Name
- Vamifeport
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21FN6O2
- CAS Number
- 2095668-10-1
- Unique Ingredient Identifier
- FUF66UD0KR
- Background
Vamifeport is being investigated for the treatment of beta-thalassemia.
Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 22
- Registration Number
- NCT06726863
- Locations
- 🇬🇧
Investigator Site 82600083, Leeds, West Yorkshire, United Kingdom
Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05077436
- Locations
- 🇬🇧
Labcorp Clinical Research Unit Ltd., Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath